Odyssey Math Tuition offers H2 Math online courses for JC 1 and JC 2 students in Singapore, featuring a proprietary ...
Q3 2025 Earnings Call Transcript October 28, 2025 Operator: Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across ...
Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsCamilla Zuckero - Vice President of Investor ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
The Sunshine Coast is at the forefront of medical science, with the establishment of a new research hub spearheading advances in the treatment of ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...
The oncology adjuvants market is expanding due to rising cancer rates, personalized medicine demand, and advances in ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback